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Abstract
Introduction: Basaloid squamous cell carcinoma (BSCC) is a rare subtype of squamous cell 
carcinoma (SCC). Because of its rarity, both clinical and prognostic features of this variant 
are not well known. 
Objective: In this study, we aimed to determine the frequency of BSCC and other SCC variants 
among all laryngeal SCC cases, and to determine clinical and prognostic features of BSCC 
variant. Study design: retrospective cohort study. Evidence level: Level 2b. 
Material and methods: Records of the patients who had laryngeal SCC surgically treated at 
our institute between 2007 and 2013 were retrospectively reviewed. 
Results: Among 198 subjects who had laryngeal SCC surgically treated, the frequency of the 
variants of SCC other than classical variant was 10.1% (20/198). The most common SCC vari-
ant was BSCC (6.6%). Eleven (84.6%) patients with BSCC were at an advanced stage at the 
presentation (p > 0.05). The 3-year overall survival and disease-free survival rates were 63% 
and 53% respectively. 
Conclusion: BSCC variant may be more common than previously reported. Since almost the 
half of patients experiences disease recurrence in the early period, multimodal treatment 
strategies should be employed at initial treatment, and a close follow-up is strongly recom-
mended for this aggressive SCC variant. 
© 2014 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier 
Editora Ltda. All rights reserved.
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O basaloide variante do carcinoma de células escamosas da laringe
Resumo
Introdução: O carcinoma escamoso basaloide (CEB) é um raro subtipo do carcinoma de célula 
escamosa (CCE). Em decorrência de sua raridade, os aspectos clínicos e prognósticos dessa 
variante não são bem conhecidos. 
Objetivo: Determinar a frequência de CEB e de outras variantes do CCE entre todos os casos de 
CCE da laringe, assim como os aspectos clínicos e prognósticos da variante CEB.
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Introduction
Squamous cell carcinoma (SCC) is the most common ma-
lignancy of the upper aerodigestive tract (UADT), and 
basaloid variant is a rare subtype. In 1986, BSCC was 
first described by Wain et al. as a distinctive SCC vari-
ant with an aggressive behavior.1 In the head and neck 
region, the most common sites of involvement for BSCC 
are epiglottis, piriform sinus and base of the tongue.2,3 
Other less common sites of origin are oral cavity, tonsils, 
sinonasal tract, nasopharynx, and trachea.2,3 Since the 
first cases were described by Wain et al., approximately 
a hundred of cases of BSCC have been reported at laryn-
geal location in a 25-year period.4 
According to previous reports, these tumors often 
present at an advanced T (tumor) stage.4 Another char-
acteristic of this histological variant is the presence of 
common regional metastases at its presentation.4 In ad-
dition, distant metastases are not rare with this histo-
logical subtype, and they result in aggressive behavior 
and poor prognosis, which is characteristic of this type 
of tumor, according to most authors.1-4
In this report, we aimed to determine the frequency 
of BSCC and other SCC variants among all laryngeal SCC 
cases, and to determine clinical and prognostic features 
of BSCC variant.
Materials and methods
The development of this study took place in complete 
agreement with the Declaration of Helsinki and with the 
International Conference on Harmonization/Good Clini-
cal Practice guidelines and it was approved by the local 
ethics committee. Records of the patients who had la-
ryngeal SCC surgically treated at our institute between 
2007 and 2013 were reviewed retrospectively. Since dis-
tinction of basaloid variant and other variants could be 
difficult or erroneous in small specimens, patients who 
were only subjected to biopsy, and treated with radia-
tion/chemoradiation were excluded. Subjects who had 
any malignancy other than laryngeal SCC were also ex-
cluded. According to the tumor stage, to the patient and 
to the tumor variables, the study patients had laser/
laryngofissure cordectomy, partial laryngectomy, total 
laryngectomy or laryngopharyngectomy. The diagnosis 
of BSCC was made according to the criteria defined by 
Wain et al.1 Clinical data regarding age, gender, alcohol 
and tobacco use, stage, treatment, and follow-up were 
reviewed. Clinical and pathological TNM staging of the 
tumors were done appropriately according to the 6th and 
7th editions of AJCC Cancer Staging Manual. The surveil-
lance was performed according to the NCCN guidelines. 
Statistical analysis were performed with SPSS Sta-
tistics 20.0 package. Kaplan-Meier survival analysis was 
performed to evaluate overall survival (OS), disease 
specific survival (DSS) and disease free survival (DFS). 
Data regarding disease status in the end of the follow-up 
were entered as “no evidence of disease”, “alive with 
disease”, “died from disease”. The “event” in Kaplan 
Meier survival analysis was ‘‘death’’ for the calculation 
of overall survival, ‘‘death due to disease’’ for the es-
timation of disease specific survival and “local or sys-
temic recurrence of the disease” for the calculation of 
the disease free survival. One of the cases (subject #1) 
has been lost to follow-up and included in the case list 
as the worst outcome. Fisher’s exact test was used to 
evaluate the difference of advanced stage presentations 
between BSCC and classical SCC variant subjects. Sta-
tistical significance of p < 0.05 was taken as criterion.
 Results
There were 421 patients diagnosed and treated with la-
ryngeal cancer between 2007 and 2013. The numbers of 
patients were 115, 136, 89 and 81 on stage I, II, III and 
IV respectively. Among those 421 patients, 198 subjects 
underwent surgical treatment during the review period. 
Twenty (10.1%) of them subjects had SCC variants (Ta-
ble 1), among those, 13 (6.6%) had the basaloid variant 
of SCC. The average age was 63.2 ± 9.8 (range: 44-77) 
years, and all subjects were males. 
All of the subjects had smoking history, but none had his-
Materiais e métodos: Trata-se de um estudo de coorte retrospectivo. Nível de evidência: 2b 
Os registros dos pacientes tratados cirurgicamente para CCE de laringe em nossa instituição 
entre 2007 e 2013 foram retrospectivamente revisados.
Resultados: Foram anotados 198 pacientes tratados cirurgicamente para CCE de laringe. A 
frequência das variantes de CCE diferentes da variante clássica foi 10,1% (20/198). A va-
riante de CCE mais comum foi CEB (6,6%). Por ocasião da apresentação inicial, 11 (84,6%) 
pacientes com CEB estavam em estágio avançado (p > 0,05).  Os percentuais de sobrevida 
geral após três anos e de sobrevida livre da doença foram 63% e 53%, respectivamente. 
Conclusão: A variante CEB pode ser mais comum do que o informado anteriormente. Con-
siderando que praticamente metade dos pacientes sofre recorrência da doença em seu 
período inicial, devem ser introduzidas estratégias terapêuticas multimodais no tratamen-
to inicial; além disso, recomendamos enfaticamente um cuidadoso seguimento para essa 
agressiva variante do CCE.
© 2014 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Publicado por Elsevier 
Editora Ltda. Todos os direitos reservados.
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tory of chronic alcohol use. The demographic data, including 
DJHFOLQLFDODQGSDWKRORJLFDO710FODVVLÀFDWLRQVDQGVWDJHV
of the subjects are presented in Table 2. Two subjects (15%) 
had early stage (Stage I/II) laryngeal cancer, while 11 (85%) 
had advanced stage (Stage III/IV). In contrast, among 178 or-
dinary laryngeal SCC subjects surgically treated in the same 
period, 30% were on early stage, and 70% were on advanced 
stage laryngeal cancer. The rates of cases on advanced stage 
DWWKHGHWHFWLRQDUHQRWVLJQLÀFDQWO\GLIIHUHQWDPRQJEDVD-
loid and classical SCC groups (p = 0.353) 
All subjects were diagnosed with laryngeal cancer at 
presentation except for the subject #2. This subject was 
presented with a neck mass of unknown primary and under-
ZHQWQHFNGLVVHFWLRQDWÀUVWDQGKDGUDGLRWKHUDS\+HKDG
total laryngectomy four months after primary treatment 
due to a late presenting glottic tumor as primary focus. 
The tumors were glottic, supraglottic, and transglottic 
LQÀYHÀYHDQGWKUHHVXEMHFWVUH-
spectively. One subject (Subject #1) was lost to follow-up 
(LTF) after 12 months. The average follow-up time was 28.7 
± 11.9 (range, 15-51) months (LTF subject was excluded). 
At the time of diagnosis, two subjects (Subjects #4 and 7) 
were N+ (Table 2). The operations performed are also sum-
marized in Table 2. The most common operation was total 
laryngectomy (84.6%) due to advanced T stages. 
'HÀQLWLYHGLDJQRVLVRI%6&&ZDVPDGHDIWHUH[DPLQDWLRQ
of the main surgical specimen. The punch biopsy investiga-
WLRQVEHIRUHWKHPDLQVXUJHU\KDGFRUUHFWO\LGHQWLÀHG%6&&
in only two cases, however two cases were erroneously 
LGHQWLÀHGDVSDSLOODU\YDULDQWDQGWKHUHPDLQLQJQLQHDVWKH
classical variant. The average of the largest tumor diameter 
was 3.05 ± 1.12 cm (range, 2-5 cm) in the BSCC patients. 
None of the patients with BSCC have HPV positivity.
Postoperative complications developed in two subjects: 
RQHSKDU\QJRFXWDQHRXVÀVWXOD VXEMHFWDQGRQHFK\-
ORXV ÀVWXOD VXEMHFW  %RWK ZHUH VXFFHVVIXOO\ WUHDWHG
with conservative therapy.
Recurrence was observed in 5 subjects (38%). Loco-re-
gional recurrence developed in three subjects and distant 
metastases were seen in two subjects (Table 2). 
Two subjects (subjects #11 and #13) had previous treat-
ment for laryngeal carcinoma. Subject #13 had concomi-
Table 1 The distribution of variants larynx squamous cell  
carcinoma (SCC).
Variant N %
Basaloid SCC 13 65
Verrucous SCC 2 10
Spindle Cell SCC 2 10
Papillary SCC 1 5
Acantholytic SCC 1 5
Adenosquamoous SCC 1 5
Total 20 100
Figure 1.DSODQ0HLHUVXUYLYDOFXUYHVKRZLQJGLVHDVHVSHFLÀF
survival for 13 patients.
Figure 2 Kaplan Meier survival curve showing disease-free 
survival for 13 patients.
tant chemo-radiotherapy and recurrence seven months af-
ter the initial treatment. Subject #11 had radiotherapy for 
early-stage supraglottic larynx carcinoma and experienced 
recurrence nine months after the initial treatment.
All patients who have died were dead because of the dis-
HDVHVRRYHUDOOVXUYLYDODQGGLVHDVHVSHFLÀFVXUYLYDOWLPHV
were the same. The Kaplan Meier survival curves depicting 
the DSS and DFS are shown in Figure 1 and 2. The 3-years 
OS rate was 63%. The 3-years DFS rate was 53%. The 3-years 
OS rate and DFS rate for the patients with other squamous 
cell carcinomas who has undergone surgery was 77% and 61% 
respectively.
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Table 2 Clinical and prognostic data of the studied subjects.
Case
Age 
(years)
Loca-
tion
Surgical Procedure LV inv PN inv
Regional 
metas-
tases
Metastatic Nodes cTNM pTNM Stage
Follow-up 
(months)
Local/Regional 
recurrence
Distant 
metastase
1 44 SG SL+Bil SND (zones 2,3,4) - - - - T2N0 T2N0 II LFU None None
2 75 GL
Left MRND (CN IX), 4 
months later TL+ Right 
Hemithyroidectomy + 
Right SND (zones 2,3,4)
- - +
One lymph node in 
ipsilateral zone 2, three 
lymph nodes in ipsilateral 
zone 4 andfive lymph nodes 
in ipsilateral zone 5
T4aN0 T4aN0 IVA 32, DOD
Peristomal 
recurrence after 
seven month
None
3 51 TG
TL + Bil SND (zones 
2,3,4)
- - - - T4aN0 T4aN0 IVA 51, AWD
Metestatic lymph 
node in zone 1 af-
ter nine months/
Treated with neck 
dissection
None
4 71 SG
TL+Right MRND (CN IX), 
+ Left SND (zones 2,3,4)
- - +
One lymph node in each 
zone 3
T3N2c T3N2c IVA 37, AWD None None
5 77 GL TL + Left MRND (CN IX), - - - - T4aN0 T4aN0 IVA 37, AWD None None
6 63 GL
TL + Bil SND (zones 
2,3,4)
- - - - T4aN0 T2N0 II 36, AWD None None
7 63 TG TL + Left MRND (CN IX) + + +
One lymph node in 
ipsilateral zone 4
T4aN1 T4aN1 IVA 35, AWD None None
8 62 SG TL + Bil SND (zones 2,3,4) - - - - T3N0 T3N0 III 34, AWD None None
9 76 GL
TL + Bil SND (zones 
2,3,4)
- - - - T4aN0 T4aN0 IVA 24, DOD
Peristomal 
recurrence after 
12 months
None
10 63 GL
TL + Total 
Thyroidectomy + Bil 
SND (zones 2,3,4) + 
Zone 6 dissection
- - - - T4aN0 T4aN0 IVA 12, DOD None
Lung 
metestasis 
after three 
months
11 59 TG
TL + Right MRND 
(CN IX), + Left SND 
(zones 2,3,4) + Right 
Hemithyroidectomy
+ + - - rT3N0 T3N0 III 16, AWR None
Lung 
metestasis 
after eight 
months
12 61 SG SL+Bil SND (zones 2,3,4) - - - - T2N0 T4aN0 IVA 16, AWD None None
13 58 SG TL + Bil SND (zones 2,3,4) - - - - rT3N2c T4aN0 IVA 15, AWD None None
LV inv, lymphovascular; PN inv, perineural invasion; ART, Adjuvant Radiation Therapy; DOD, Died Of Disease; AWD, Alive Without Disease; AWR, Alive with Reccurence; SG, Supraglottic; 
GL, Glottic; TG, Transglottic; FND, Functional Neck Dissection; CN, Cranial Nerve; Bil, Bilateral; MRND, Modified Radical Neck Dissection.
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Discussion
Histopathologically, the BSCC is characterized by nests of 
basal-type squamous tumoral cells that classically have cen-
tral necrosis. In a certain small biopsy specimen, when this 
classical morphology is not observed, the initial patholog-
ical diagnosis would be an ordinary SCC of varying grade. 
Because this subtype may be associated with a relatively 
worse prognosis, the biopsy diagnosis can be considered to 
have more importance. In our series of 13 histopathologi-
FDOO\SURYHQFDVHVWKHÀQDOGLDJQRVHVIRUSDWLHQWVZHUH
established in the resection specimens. Only 2 cases were 
diagnosed as basaloid type SCC in the initial endoscopic bi-
opsy samples. The most credible explanation for this dis-
crepancy between the biopsy and resection samples is that 
a basaloid or papillary SCC quite expectedly might contain 
foci of ordinary SCC morphology and unless the initial biop-
sy has areas representing the characteristic morphology for 
WKHGLDJQRVLVRIDVSHFLÀFVXEW\SHDVPDOOVDPSOHFDQEH
PLVOHDGLQJ0RUHRYHUPDQ\6&&VKDYHVXSHUÀFLDOSDSLOODU\
architecture that might lead to a papillary SCC diagnosis in 
the biopsy sample. For an SCC to be diagnosed as a papillary 
type SCC, the excision or resection specimen must prefera-
bly be examined; which can present a morphology consist-
ing of an SCC that predominantly has prominent papillary 
growth without a dominant SCC component that is invading 
underneath. Our series and results clearly indicate the in-
evitably-limited representation of the initial biopsy for the 
diagnosis of the correct subtype.
The most common laryngeal malignancy is SCC, which 
comprises more than 90% of the cases. Verrucous, spindle 
FHOODQGEDVDORLGVXEW\SHVDUHPXFKUDUHUYDULDQWV%6&&ÀUVW
described in 1986 and has been reported in larynx, hypophar-
\Q[RUDOFDYLW\DQGRURSKDU\Q[DWÀUVW1,3-5 Approximately 
one fourth of the cases reported within the UADT are located 
at the larynx and these cases comprise only less than 1% of 
the laryngeal cancers.4 In our series, 10% of the surgically 
treated laryngeal carcinomas were other than classical vari-
ants of SCC and 65% of all these variants were BSCC. This 
LV WKH ÀUVW VWXG\ZKLFK UHSRUWV IUHTXHQF\ RI 6&& YDULDQWV
located at the larynx and also systematically describes the 
clinical and prognostic features. Relatively high incidence of 
BSCC in our series may be related with higher awareness of 
pathologists at our institution about SCC variants. 
BSCC displays distinct morphological and biological fea-
tures and have a different clinical course.6 According to 
previous reports, it mainly affects elderly men who have 
smoking/alcohol abuse history as classical SCC.3,5,6 Ferlito 
et al. reported that the average age of the patients who 
have BSCC located at larynx or hypopharynx is 63 years.5 
Similar to the specialized literature, all the patients have 
smoking history and the average age at diagnosis was 63.2 
years in our series. 
There are some studies that reported predilection for 
the supraglottic subsite.4,7 In the present study, the fre-
quencies of supraglottic and glottic involvement were equal 
which is contradictory to those previous reports. The pa-
tients with BSCC usually present at more advanced stages 
(stage III&IV).4 In our series, 85% of the patients were at 
advanced stages. But the rate of BSCC with advanced stage 
DWSUHVHQWDWLRQLVQRWVLJQLÀFDQWO\GLIIHUHQWIURPFODVVLFDO
variant SCC group according to our results.
T1, T2 early laryngeal tumors are managed by either pri-
PDU\UDGLRWKHUDS\RUVXUJHU\ODVHUFRUGHFWRP\RUODU\QJRÀV-
sure with cordectomy). Advanced stage tumors are managed 
by either organ preserving protocols (concurrent radiother-
apy and chemotherapy) or surgery (with or without postop-
erative radiotherapy) according to patients age, pulmonary 
VWDWXVDQGSUHIHUHQFHV$FFRUGLQJWRRXUÀQGLQJVWKHLQLWLDO
biopsy showed the BSCC variant in only 2 of the 13 patients 
diagnosed as BSCC. Therefore as only 15% of the patients can 
be diagnosed with the initial biopsy, the diagnosis should al-
ZD\VEHGHIHUUHGWRÀQDOSDWKRORJ\&XUUHQWO\WKHVXUJHU\LV
the preferred primary treatment modality for BSCC in our 
institution. For that reason, we could not present data re-
garding the possible value of other treatment options for 
BSCC. Future controlled studies comparing the effectiveness 
of surgery versus other modalities such as chemoradiotherapy 
and/or radiotherapy may clarify this issue. 
To date, there are no clinical studies proposing a specif-
ic therapeutic strategy for management of BSCC. However 
surgery is the mainstay for the treatment of BSCC of the lar-
ynx due to advanced stage of the patients at presentation.4 
Total laryngectomy is the most commonly performed surgi-
cal procedure in the specialized literature.4 In our series, 
most of the patients were treated with surgery with post-
operative radiotherapy (92%). We performed total laryngec-
tomy in 85% of the patients. However, the type of laryngeal 
surgery and the extent of neck dissection vary according to 
the stage and metastatic pattern of the disease. Soriano et 
al. suggested an organ preservation approach with induction 
chemotherapy by considering the high risk of distant me-
tastases and the higher morbidity of surgery.8 This strategy 
should be taken with caution since the number of report-
ed patients was limited. But these patients might be good 
candidates for regimens incorporating chemotherapy and 
radiotherapy after surgery since majority of them present 
with advanced stages and many develop distant metastasis.
It is generally believed that BSCC has a worse progno-
sis than the classical form of SCC but there are also some 
contradictory reports.1,9-11 Three studies compared BSCCs 
with stage matched SCC controls. Wizenburg et al. found 
that the 2-year survival rates were 23.5% and 53% for BSCCs 
and SCCs respectively.12 In a study by Erdamar et al., 3-year 
survival rates were 50% and 72% for BSCC and SCC groups.7 
These two studies reports survival rates of BSCC cases lo-
cated at different parts of UADT. In contrast, Luna et al. 
compared 6 BSCC cases with 47 classical variant SCC cases 
of the pyriform sinus and found no survival difference.11 The 
authors concluded that survival rates would be similar to 
that of conventional SCC when the anatomical site, clinical 
stage and treatment were matched. 
The overall survival rate and disease free survival 
rate for the patients with other squamous cell carcino-
mas who has undergone surgery was 77% and 61% respec-
tively. This figure was much better than the overall sur-
vival rate and disease free survival rate for the patients 
with BSCC 63% and 53% respectively. Meanwhile the 
BSCC tumors present at more advanced stage compared 
to other squamous cell carcinomas. Therefore treatment 
of BSCC variant involves more aggressive therapy than 
other squamous cell carcinomas. Nevertheless despite 
more aggressive therapy, the survival was worse for BSCC 
compared to that with other squamous cell carcinomas 
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treated surgically. In our series, an aggressive behavior 
of the BSCC cases was observed. There were four high-
ly mortal events within a year: two stomal recurrences 
(15.4%) and two distant metastases (15.4%). Compared 
to the specialized literature, these rates are higher. Sto-
mal recurrence following primary total laryngectomy for 
squamous cell carcinoma occurs in 2%–6%.13,14 The inci-
dence of distant metastasis varies according to the site 
of the primary tumor: 3.1% to 8.8% in glottic SCC, and 
3.7% to 15% in supraglottic SCC.15
Conclusion
According to our series, BSCC of the larynx may not be as 
rare as previously reported. As the awareness of the path-
olologists increases, the true incidence may be revealed. 
Aggressive behavior in the form of stomal recurrence or dis-
WDQWPHWDVWDVHVZLWKLQ WKHÀUVW\HDURI WKHSRVWRSHUDWLYH
period is as high as 30%. Three-year DFS was 53% in our se-
ries, and this rate is lower when compared to the previous 
reports regarding laryngeal SCC cases.8 Another character-
istic of this SCC variant is advanced stage at presentation. 
As a result multimodal treatment strategies would be em-
ployed at initial treatment and close follow-up is strongly 
recommended according to our experience.
&RQÁLFWVRILQWHUHVW
7KHDXWKRUVGHFODUHQRFRQÁLFWVRILQWHUHVW
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